Literature DB >> 10770814

Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs.

J S Elborn1, R J Prescott, B H Stack, M C Goodchild, J Bates, C Pantin, N Ali, D J Shale, M Crane.   

Abstract

BACKGROUND: A previous retrospective study suggested that a policy of regular anti-pseudomonal antibiotic treatment improved pulmonary function and increased survival in patients with cystic fibrosis chronically infected with Pseudomonas species. The results of a prospective multicentre study to compare the effects on pulmonary function and mortality of three monthly elective anti-pseudomonal antibiotic treatment with conventional symptomatic treatment are reported.
METHODS: Sixty patients with cystic fibrosis, chronically infected with P aeruginosa, were randomised to the two treatment arms (elective or symptomatic) and followed clinically at yearly reviews. The major end points were changes in forced expiratory volume in one second (FEV(1)) and forced vital capacity (FVC). Survival was a secondary end point.
RESULTS: Patients in the symptomatic group received a mean of three antibiotic treatments each year and those in the elective group received four antibiotic treatments during each year of the study. No significant differences in FEV(1) and FVC were found between the two groups after three years. There was a statistically non-significant higher rate of deaths in the elective group (n = 4), three of which were associated with B cepacia infection, compared with the symptomatic group (n = 0).
CONCLUSIONS: This study did not demonstrate an advantage of a policy of elective antibiotic treatment over symptomatic treatment in patients with cystic fibrosis chronically infected with Pseudomonas species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770814      PMCID: PMC1745744          DOI: 10.1136/thorax.55.5.355

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  17 in total

1.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

2.  Burkholderia cepacia: another twist and a further threat.

Authors:  A K Webb; J R Govan
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 3.  Management of pulmonary disease in patients with cystic fibrosis.

Authors:  B W Ramsey
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

Review 4.  Antimicrobial treatment of pulmonary colonization and infection by pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  M Denton; M H Wilcox
Journal:  J Antimicrob Chemother       Date:  1997-10       Impact factor: 5.790

5.  Nutrition and survival in cystic fibrosis.

Authors:  J S Elborn; S C Bell
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

6.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1997-05

7.  Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre.

Authors:  M Nir; S Lanng; H K Johansen; C Koch
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

8.  Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

Authors:  M Szaff; N Høiby; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1983-09

9.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

10.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

View more
  13 in total

1.  Acute renal failure in people with cystic fibrosis.

Authors:  Kevin W Southern
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

2.  Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis.

Authors:  E Hatziagorou; V Avramidou; F Kirvassilis; J Tsanakas
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

Review 3.  Recent advances in cystic fibrosis.

Authors:  I J Doull
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

Review 4.  Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.

Authors:  Lil Breen; Nivedita Aswani
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.

Authors:  N Høiby
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 6.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

7.  Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.

Authors:  J Riethmueller; M Ballmann; T W Schroeter; P Franke; R von Butler; A Claass; S Junge; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553

Review 8.  Exacerbations in cystic fibrosis: 2 . prevention.

Authors:  Scott C Bell; Philip J Robinson
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

9.  Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.

Authors:  Donald R Vandevanter; David E Geller
Journal:  Med Devices (Auckl)       Date:  2011-09-20

Review 10.  Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Authors:  Matthew N Hurley; Andrew P Prayle; Patrick Flume
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.